A method for campus-wide SARS-CoV-2 surveillance at a large public university.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34919584.
- Also identified by DOI 10.1371/journal.pone.0261230 and PMC identifier 8682906.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The systematic screening of asymptomatic and pre-symptomatic individuals is a powerful tool for controlling community transmission of infectious disease on college campuses. Faced with a paucity of testing in the beginning of the COVID-19 pandemic, many universities developed molecular diagnostic laboratories focused on SARS-CoV-2 diagnostic testing on campus and in their broader communities. We established the UC Santa Cruz Molecular Diagnostic Lab in early April 2020 and began testing clinical samples just five weeks later. Using a clinically-validated laboratory developed test (LDT) that avoided supply chain constraints, an automated sample pooling and processing workflow, and a custom laboratory information management system (LIMS), we expanded testing from a handful of clinical samples per day to thousands per day with the testing capacity to screen our entire campus population twice per week. In this report we describe the technical, logistical, and regulatory processes that enabled our pop-up lab to scale testing and reporting capacity to thousands of tests per day.
Medical subject headings
- COVID-19
- COVID-19 Nucleic Acid Testing
- Clinical Laboratory Techniques
- Diagnostic Tests, Routine
- Mass Screening
- Pandemics